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ABSTRACT
The aim of this study was to determine the antifungal agents and boric acid susceptibility to the
azole-resistant Candida species, as well as clinical outcomes following treatment with antifungal
agents that are commonly prescribed in Dar es Salaam and boric acid which is not available in
Tanzania market. Microscopic examination of the vaginal discharge during prolonged therapy
with three antifungal agents (clotrimazole, miconazole, and nystatin) and boric acid were carried
out. Samples were collected from 150 women of reproductive age group (13 to 45 years) with
chronic vaginal candidal infections. The samples were cultured in Sabouraud’s dextrose agar
(supplemented with 0.005% chloramphenicol and 0.05% cycloheximide) followed by aerobic
incubation for 48 hours at 37
º
C in order to obtain pure cultures. Identification was done by Gram
stain, while the test for ability to ferment and assimilate different sugars was done on API Candida
and API 20C AUX. The stock cultures of Candida albicans (ATCC 32354), Candida glabrata
(ATCC2001) and Candida guilliermondii (ATCC6260) were used as controls. Patients were
dispensed together with 10 ml syringes for self douching of boric acid solution, and three
commonly used antifungal vaginal drugs for Candida vaginitis. The results revealed a total of 167
Candida species dominated by C. albicans 116 (69.46%), followed by C. glabrata 21 (12.57%), C.
krusei 8 (4.8%), C. tropicalis 7 (4.2%), C. famata 6 (3.59%), C. lusitaniae 5 (3.0%), C.
parapsilosis, Trichosporon 2 (1.2%) and C. guilliermondii 1(0.6%). The results further showed
that out of 116 C. albicans isolates, 23 (19.83%) were resistant to clotrimazole while 14 (12.1%)
were resistant to miconazole in vitro test. Interestingly, all C. albicans isolates and the non-
albicans candida species were very sensitive to boric acid at a very low MIC values (0.025µg/ml).
Generally, the overall success rate for clotrimazole in treating C. albicans infections was 41.7%,
miconazole 56.5%, nystatin 77.3% and boric acid 100%. This study shows that, compared to other
commonly used drugs in the country, the best performance of boric acid envisage the need to
update the national treatment guidelines for the treatment of Candida vaginitis.
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INTRODUCTION
Management of resistant Candida species
remains to be a challenge in clinical
practices in Tanzania and other tropical
countries where warm and humid climate
favors their survival. Epidemiologic and
susceptibility studies indicate that non-
albicans Candida species are more resistant
to treatment with conventional antifungal
drugs especially with the azole antifungal
groups and are considered as causative
pathogens of vaginal candidiasis (White et
al., 1993; Sobel, 1998a; Abu-El-teen, 2001;
Klepser, 2001; Namkinga et al., 2005a).
Treatment of vaginal candidiasis is normally
done with antifungal agents such as
polyenes (nystatin or amphotericin-B);
imidazoles (clotrimazole, miconazole,
econazole, and ketoconazole); triazoles
(fluconazole, itraconazole & voriconazole)
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and other antimetabolites (White et al. 1998,
Namkinga et al. 2005a).
Despite this wide array of antifungal drugs,
there have been several reports indicating
that vaginal candidiasis is refractory to
treatment and the development of recurrence
cases is common (Sheehan et al. 1999, Abu-
El-teen 2001). Several reasons for these
trends have been attributed to increased
incidences of vaginal candidiasis associated
with non-albicans Candida species such as
C. glabrata, C. krusei, C. tropicalis and C.
lusitaniae (Hazen 1995, Sobel 1998b, Abu-
El-teen 2001); uncontrolled consumption of
antifungal preparations resulting in
secondary, resistance, i. e. increasing usage
of short course antifungal therapies and
inadequate treatment or poor patients
compliance (Jovanovic et al. 1991, Johnson
et al. 1995, Rex et al. 1995, Silverman et al.
2001). Other factors include extensive use of
broad spectrum antibiotics (Nasibwa et al.,
1994) and immune-suppression e.g.
increased prevalence of HIV infection
(Spinillo et al. 1994, Sullivan et al. 1996,
Baily et al. 1997, Pfaller et al. 1 9 9 7 ,
Nwokolo and Boag 2000); contraceptive use
(Baeten et al. 2001) and to a lesser extent
c o r t i c o s t e r o i d s  a n d  o t h e r
immunosuppressive drugs (Baeten et al.,
2001). Putative factors associated with
vaginal candidiasis include; pregnancy and
uncontrolled diabetes (Sobel 1992, Ringdahl
2000, De Leon et al. 2002), poor hygiene
and promiscuity (Ginter et al. 1992, Spinillo
et al. 1993; Marin et al. 2000, Ringdahl
2000); iron deficiency anaemia (Higgs and
Wells 1972) and allergies from condom
usage or type of clothes used for underwear
(Eckert et al. 1998). However, there are
cases of vaginal candidiasis without a
recognizable predisposing factor (Sobel,
1998a). It has been postulated that allergy
(Moraes, 1998), or certain blood groups
(Chaim et al. 1997), or the usage of
commercially available solutions for vulvo-
perneal cleaning or vaginal douching could
be the cause for occurrence or recurrence of
vaginal candidiasis in such women (Spinillo
et al. 1993).
Typical symptoms for vaginal candidiasis
include; pruritus vulvae often during
premenstrual period, vulval soreness,
erythema and production of non-odorous
thick discharge (cheese-like caseous white to
yellowish purulent adherent plaques on the
vaginal, vulval, or cervical epithelium),
dysuria and dyspareunia (Gough et al. 1985,
Sobel 1981, 1992, 1993, Denning 1995,
Namkinga et al. 2005a,b). Although pruritus
and inflammation of the vaginal introitus are
typical symptoms, only less than 50% of
women with genital pruritus suffer from
vaginal candidiasis. It is also important to
note that, co-infections with almost similar
signs or symptoms such as trichomoniasis or
bacterial/or viral vagnosis may occur,
therefore, most of the above mentioned signs
and symptoms are not specific for the
diagnosis of vaginal candidiasis (Namkinga
et al. 2005a).
Candida vaginitis is considered to be
recurrent when at least four specific
episodes occur in one year or at least three
episodes unrelated to antibiotic therapy or
any other putative factor occur within one
year (Ringdahl 2000). Recurrent VC can be
classified as primary or secondary
depending upon established underlying
causes (Fidel and Sobel 1996). Secondary
sporadic RVC refers to those infrequent
vaginal infections precipitated by pregnancy,
or by exogenous factors such as antibiotics
or wearing of tight undergarments (Fidel and
Sobel 1996). Secondary recurrent vaginal
candidal infections commonly occur as a
result of uncontrolled diabetes mellitus,
immunosuppressive therapy, hormone
replacement therapy and possibly AIDS
(Fidel and Sobel 1996). Primary sporadic
VC and recurrent VC are idiopathic with no
known causes. However, 5-10% of women
with a primary sporadic episode of vaginitis
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will subsequently develop recurrent VC
(Hurley 1977, Hurley 1981, Fidel and Sobel
1996). Women with recurrent VC can avoid
all potential causes of acute vaginitis and
still experience repeated episodes of
vaginitis. In women with idiopathic
recurrent VC, antifungal agent therapy is
highly effective for individual attacks but
frequently fails to prevent future recurrence.
In fact, recurrent episodes of vaginitis will
appear as early as a few days to 3 months
after cessation of successful treatment in
approximately 50% of women with recurrent
VC (Fleury 1981, Sobel 1989, Fidel and
Sobel 1996, Singh et al. 1997, Sobel et al.
2003).
Molecular studies of VC have attributed the
occurrence of recurrences to either relapse
(by the same strain of C. albicans) or re-
infection with a different strain or a new
species of Candida (Powderly et al. 1993).
Relapses caused by a similar strain may be
indicative of the failure of therapy to
eradicate initial infection (colonization),
whereas those due to a new strain or new
species indicate subsequent colonization
with less susceptible organisms. Non-
albicans Candida species such as Candida
glabrata, C. dubliniensis, C. krusei and C.
tropicalis  have been associated more
frequently with recurrence of the disease
than Candida albicans (Spinillo, et al. 1995,
1999; White, et al. 1998), probably due to
the fact that they are more resistant to
treatment with antifungal agents especially
azoles (White, et al. 1998). As azole
antifungal agents have become important in
the treatment of mucosal candidiasis in
AIDS patients, reports of resistance have
increased (Law et al. 1994, White et al.
1998). In fact, azole resistance has now been
found in patients not infected with HIV and,
in some situations, in patients not previously
exposed to antifungal agent agents (Singh et
al. 1997, Sobel et al. 2003).
Several studies have documented increased
infections due to the intrinsically azole-
resistant non-albicans  Candida species
(Nguyen, et al. 1996). At one institution, C.
albicans comprised 87% of the isolates
recovered from blood prior to the use of
fluconazole (1987 to 1991) but accounted
for only 31% of the isolates in 1992, when
fluconazole was used frequently for
prophylaxis and treatment. Similarly, an
increased incidence of non-albicans Candida
species with increased azole MICs arose
over a 3.5-year study period at another
institution (Nguyen, et al. 1996). Primary
resistance to 5-FC is common in certain
yeasts and molds. Non-albicans Candida
spp., as well as Apergillus spp., C .
neoformans and the dimorphic fungi have
high rates of 5-FC resistance (Francis and
Walsh, 1992). In addition, secondary
resistance is a common development,
especially in patients receiving 5-FC mono-
therapy. There is some indication that the
severity of immune-suppression and fungal
burden especially infections with non-
albicans Candida species may be important
risk factors leading to the development of
resistance (Johnson et al. 1995; Shinohara
and Tasker, 1997). For example, in vitro
susceptibility studies of sucrose negative
Candida species showed Candida
n o v e r g e n s i s  to be more resistant to
clotrimazole, miconazole and ketoconazole
than clinical isolates of C. albicans (Ahearn
et al. 1984). Likewise, Candida lusitaniae
and Candida tropicalis show resistance to 5-
fluorocytesine and to the azoles than other
Candida  species (Ahearn et al. 1984).
Because 5-FC resistance develops
frequently, the drug should never be used as
a single agent to treat either yeast or mold
infections.
Candida vaginitis (CV) is a common
condition and usually straight forward to
treat. In contrast, complicated CV can be
intractable and cause considerable
psychological morbidity. Complicated CV
Namkinga – Management of Azole-Refractory Candida Species Using Boric Acid Preparations …
126
includes recurrent or severe disease, or when
there are adverse factors in the host. This
includes persistent infection with species
other than Candida albicans, (‘non-C
albicans’) and the more common recurrent
a l b i c a n s  CV. The importance of
distinguishing the two conditions is that
non-C albicans chronic vaginal yeast
infection is potentially resistant to treatment
with azole antifungal agents such that newer
approaches or drugs may be needed in
treatment. This study attempted to correlate
the i n  vitro susceptibility with treatment
success of the azole refractory Candida
species using boric acid.
Materials and methods
A total of 150 women of reproductive age
group (13 to 45 years of age) with chronic
vaginal candidal infections were followed up
with microscopic examination of the vaginal
discharge during prolonged therapy with
antifungal agents and boric acid.
Preparation of isolates
The isolates were inoculated on Sabouraud’s
dextrose agar (SDA) (Oxoid Ltd.
Hampshire, England), supplemented with
0.005% chloramphenicol and 0.05%
cycloheximide and incubated aerobically for
48 hours at 37ºC in order to obtain pure
cultures. The isolates were identified by
Gram stain, germ tube production on horse
serum (Oxoid, Hampshire, England), conidia
enhanced morphology on corn meal agar
(Oxoid Ltd. Hampshire, England), ability to
ferment and assimilate different sugars on
API Candida (BioMerieux SA, France) and
by API 20C AUX (BioMerieux SA, France).
Stock cultures of Candida albicans (ATCC
32354), Candida glabrata (ATCC2001) and
Candida guilliermondii (ATCC6260) were
used as controls.
Boric acid susceptibility/resistance test
The susceptibility to boric acid was assessed
by incorporating the boric acid into an agar
plate at a concentration of 1%. The inocula
for this test were prepared by sub-culturing
the isolates onto Sabouraud’s dextrose agar
(Oxoid Ltd. Hampshire, England),
supplemented with 0.005% chloramphenicol
and 0.05% cycloheximide and incubated
aerobically for 48 hours at 37
0
C, observing
after every 24 hours in order to obtain pure






Mc Farland concentrations) was prepared. A
synthetic swab was used to inoculate the
suspension onto Mueller Hinton agar
containing 1% boric acid. A control plate
which contains only the basal medium
without boric acid was inoculated
simultaneously. Control organisms were also
inoculated. The test plates and control plates
were then incubated aerobically for 48 hours
at 37
º
C, after which each isolate was scored
as being resistant (R), moderately resistant
(MR), moderately sensitive(MS) or sensitive
(S) to boric acid, as indicated by the
presence or absence of confluent growth.
Preparation of boric acid solution for in
vivo test for patients
A sufficient amount of boric acid powder
(Sigma Chemical co., St. Louis, USA)
enough to make a 1% solution was weighed
on a OHAUS-triple beam balance 700 series
of capacity 2610 g (USA). The powder was
then dissolved in a bacteria-free water of
70
0
C previously sterilized by autoclaving.
The boric acid solution was then filled and
capped into 100 ml pet cumber amber glass
bottles. Preparation of the boric acid solution
was done in a factory (AA-Dispensing &
Manufacturing Company) with permission
from Tanzania Food and Drug Authority
(TFDA) and requested by the Board of
Registrar (Tanzania) following good
manufacturing practice (GMP) and standard
operating procedures (SOPs). The bottles
were then labeled indicating the name of
preparation, strength, amount, dosage, batch
number, manufacturing and expiry dates,
and company name and address. Patients
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were dispensed together with 10 ml syringes
for self douching of boric acid solution.
Azole antifungal susceptibility/resistance
test
Three commonly used antifungal vaginal
drugs for Tanzania market, namely;
Clotrimazole, miconazole and nystatin in
different brands in a form of pessaries and
ovules were used in the study. Women with
Candida vaginitis were separated into four
groups depending on the antifungal agent
drug administered. Dosage used were;
clotrimazole pessaries (100 mg) inserted
deeply into the vagina in the evening on 6
consecutive days; miconazole ovules (400
mg) inserted daily into vagina at bed time
for 3 consecutive days; and nystatin vaginal
pessaries (100,000 IU) inserted into the
vagina for 14 consecutive nights regardless
of any intervening menstruations.
Treatment evaluation
All patients were requested to return for
assessment two weeks after treatment was
completed. On this occasion, symptoms and
clinical signs of vaginitis (the vagina
mucosa was reddened, or granular; the vulva
inflammation was reddened, swollen,
fissured or ulcerated), were noted and high
vaginal swabs were taken for mycological
investigation. Patients were monitored for
two consecutive months on the type of drugs
taken, and laboratory analysis of the
Candida species carriage. Patients with poor
response to the azoles were then given
nystatin vaginal preparation on the second
month of visit to the clinic. Again if the
response was poor to nystatin, the patient
was subjected to treatment with boric acid
solution. Assessment of treatment was based
on mycological and clinical criteria.
Mycological cure was defined as negative or
low (less than 10 colonies on Mueller
Hinton agar plates) culture result (Odds et
al. 1987), while clinical cure was regarded
as absence of clinical signs and symptoms
associated with Candida vaginitis (Milne
and Warnock 1979). Treatment was
considered to be successful if both clinical
and mycological cure were achieved.
Standard powders
Miconazole (Janssen Research Laboratory,
Belgium), clotrimazole (BUFA, B. V.
Pharm. Product, Uitgeest, Holland) and
nystatin (BUFA, B. V. Pharm. Product,
Uitgeest, Holland) together with boric acid
were tested for in vitro susceptibility against
Candida species. The isolates used in the
analysis were Candida albicans, Candida
glabrata, Candida tropicalis, Candida
krusei, C . parapsilosis, C. famata and
Trichosporon.
Standard organisms
Candida albicans (ATCC 32354), C. krusei
(ATCC 6258), C. parapsilosis (ATCC
22019) and C. glabrata (ATCC 2001) were
used as standards in this study.
Patient’s specimens
A  gynaecological examination was
performed by a physician at Masana
Hospital, Dar es Salaam, Tanzania and
women were told to come after two weeks
for their results. High vaginal swabs were
collected and placed in Stewart’s transport
media for laboratory diagnosis of Candida
vaginitis. All specimens were processed in
the Department of Molecular Biology and
Biotechnology at the University of Dar es
Salaam, Tanzania. The wet mounts were
prepared and examined microscopically for
the presence of yeast cells. Gram stained
smears were also prepared. Provisional
detection of Candida spp. was based on
colonial morphology on Sabouraud dextrose
agar (SDA) media containing 0.005%
chloramphenicol and 0.05% cycloheximide.
Ethical clearance
This is a continuation of projects from a
PhD study which was ethically approved by
the College Research and Publications
Committee of the Muhimbili University
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C o l l e g e  o f  H e a l t h  S c i e n c e s ,
(MU/PGS/AEC/III/126 of November 11,
1997). Older samples (1997 – 2003)
resistant to azoles were used as control while
the current samples (2012) were used as test
organisms.
RESULTS
A total of 167 Candida species were isolated
from 50 samples out of which C. albicans
were 116 (69.46%), C. famata 6 (3.59%), C.
t rop i ca l i s  7 (4.2%), C. glabrata 21
(12.57%), C. krusei 8 (4.8%), C. lusitaniae 5
(3.0%), C. parapsilosis and C .
g u i l l i e r m o n d i i  1(0.6%) each, and
Trichosporon 2 (1.2%). Out of 116 C .
albicans isolated, 23 (19.83%) were resistant
to clotrimazole and 14 (12.1%) were
resistant to miconazole in vitro test. The
total of 18 (15.5%) isolates of C. albicans
were moderately resistant to azole antifungal
agents (clotrimazole and miconazole), and
78 (67.24%) were susceptible to azoles
tested (Fig. 1e). From 6 isolates of C. famata
tested, 5 (83.33%) were resistant to azoles
(Fig. 1b). As for C. lusitaniae, C.
guilliermondii and C. krusei (Fig. 1d), all
were resistant to azoles in vitro testing. Out
of seven C. tropicalis isolates tested 4
(57.14%) were resistant to azoles, 1 (14.3%)
moderately resistant, 1 (14.3%) moderately
susceptible and only 1 (14.3%) was
susceptible to azoles (Fig. 1c). Candida
p a r a p s i l o s i s  and Trichosporon  were
resistant to clotrimazole only. All isolates
(C. albicans and the non-albicans candida
species) were very sensitive to boric acid at
a very low MIC values 0.025 µg/ml (Fig. 1a
- g). Also, the old samples (1998-2003),
which were resistant to azoles, were now all
susceptible to boric acid.
Figure 1a.
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Figure 1g
Figure 1(a-g): Susceptibility Pattern of diverse Candida species to antifungal drugs commonly
available in Tanzania market and boric acid which is not in the market. The vertical
line represents the number of isolates against types of drugs used; Clotrimazole,
Miconazole (azoles), Nystatin and Boric acid. (S= Susceptible; MS = moderately
susceptible; R = resistant; MR = moderately resistant).
Treatment in vivo success rates
The overall success rate of clotrimazole in
treating C. albicans infections was 41.7%,
being 40.0% and 50.0% at MIC values !0.8
"g/ml and 1.6 "g/ml, respectively.
Miconazole was effective in treating 56.5%
of C. albicans infections. The overall
success rate of nystatin was 77.3%; all
isolates had MIC values of !0.8 "g/ml.
Azoles had less success rate in treating C.
albicans infections. For Candida glabrata
infections, the overall success rate for
miconazole was 16.7%, being 0.0% at MIC
values of !3.2 "g/ml, and to 50% at MIC
values of #6.4 "g/ml. The same fungus,
when subjected to clotrimazole, recorded a
success rate of 0.0% at all MIC values,
while for nystatin it was 67.0% (overall),
66.7% (MIC value of !0.8 "g/ml), and 0.0%
at MIC value of 1.6 "g/ml. For Candida
tropicalis infections, the overall success rate
with miconazole was 50%, being 33.3% at
MIC !0.8 "g/ml and 100% at MIC 3.2
"g/ml. With clotrimazole the success rates
were 25% and 0.0%, respectively. The
overall success rate of treating C. tropicalis
infection with nystatin was 50% being
66.7% at !0.8 "g/ml and 50% at #6.4 "g/ml.
For C. krusei infections, the overall success
rates were 56.6%, 10%, and 0% for nystatin,
miconazole and clotrimazole, respectively.
C. parapsilosis, C. norvegensis and C .
famata infections, were rather few and all
their isolates had very high MIC values
(!3.2 "g/ml), and their treatment success
with azoles was very poor. The success rates
for C. parapsilosis and Trichosporon were
0.0% and 100% with clotrimazole and
nystatin, respectively. Treatment success
rate for C. norvegensis were 100% for
nystatin and 0.0% for clotrimazole, while for
C. famata success rate was 5% for
clotrimazole and Miconazole and 100% for
nystatin and boric acid.
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DISCUSSION
The in vitro susceptibility patterns of the
isolates were determined by three methods
namely; disk-diffusion, agar dilution and the
reference broth macro dilution technique.
The agar dilution and disk diffusion methods
were included since they are feasible in our
routine laboratory and could potentially
serve as alternatives to the reference broth
macro dilution method. The disk diffusion
method showed good agreement with the
tube macro dilution method, which is in
keeping with other findings, (Yucesary, et
al. 2001; Lee, et al. 2001; Barry, et al.
2002), and appears to be a useful, rapid and
reliable screening technique for testing the
susceptibility of clinical isolates to
imidazoles, polyenes and even boric acid.
The incidence of resistance to treatment of
vaginal fungal infections in women has
increased dramatically in Tanzania as has
the number and variety of infecting fungal
species or strains. Results of this study
concur with several other investigators’
reports encountering increased numbers of
women with vaginal fungal infections
caused by non-albicans Candida species
(Sobel, 1985; Sobel et al. 1995, 1998).
Although Candida vaginitis is a very
common condition in women, and usually
straight forward to treat, complicated CV
that leads to recurrences can be intractable
and cause considerable psychological
morbidity.
Treatment failure, attributable to the
development of azole-resistant C. albicans
strains, appears to become more common,
but still seems to be confined to patients
receiving long-term treatment. Majority of
HIV positive women in Tanzania receive
Fluconazole prophylaxis which might be the
cause for the development of Candida
vaginitis by the non-albicans Candida
species. The rapid development of drug
resistance and the persistence in patients
with the non-albicans Candida species such
as C. glabrata, C. parapsilosis, C. tropicalis,
C. lusitaniae, C. famata or C. krusei
infections to treatment with azole antifungal
drugs is of concern and high lights the need
for accurate identification of organisms
before commencing treatment. Results of
this study showed that treatment with boric
acid vaginal preparation was of value in
recalcitrant cases (Figure 1 a-g) which is in
line with other studies (Redondo-Lopez et
al. 1990, Sobel and Chaim 1997, Shinohara
and Tasker, 1997; Guaschino et al. 2001;
Lavazzo et al. 2011), which suggested that
boric acid is safe, cheap and is the best
alternative in the management of non-
albicans Candida species.
The non-albicans Candida species and some
few C. albicans 23 (19.83%) showed rather
high MIC values (! 12.8 µg/ml), indicating
that the isolates were resistant. Such isolates
are likely to have been isolated from either
patients who had received prior courses of
anti-fungal therapy (or could as well be
associated with the intrinsic resistance of
these species to azoles as it has been also
noted by Rex et al. (1995), White et al.
(1998), Sheehan et al. (1999), Davies et al.
(2012) are likely to be associated with
recurrences of Candida vaginitis. Effective
treatment of isolates with high MICs, which
is in this study belonged mostly to C .
glabrata, C. lusitaniae, C. famata, C. krusei
and C. tropicalis, is likely to base either on
combination of anti-fungal agents with
different mechanisms of action or new
antifungal agents such as voriconazole
(Kronvall and Karlsson, 2001) or boric acid.
The notable significant species differences
in vitro susceptibility to antifungal agents
seem to suggest the usefulness of speciating
Candida as a first step towards determining
appropriate anti fungal regimen.
This study attempted to correlate in vitro
susceptibility with treatment success. The
MIC values included in the correlation are
those obtained using the broth macro
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dilution technique (NCCLS M27), which is
the reference method for antifungal agent
susceptibility testing (Pfaller et al. 1997,
Rex et al. 2001). This method has been
studied extensively to examine the roles of
variables such as inoculum preparation,
inoculum size, medium composition,
incubation temperature and incubation time.
As a result, it produces results that are
comparable in quality with those of
antibacterial susceptibility testing (Pfaller et
al. 1997).
A notable observation was the fact that boric
acid had better treatment success for non-
albicans infections than the azoles. Also, the
control samples (of the year 1998-2003)
which were resistant to azoles were now
susceptible to boric acid. It is postulated that
the fungistatic or fungicidal effects of boric
acid may be a result of its inherent
properties as a weak acid. The acid
penetrates the cell wall and disrupts the cell
membrane, whereas current antifungal
agents bind and inhibit ergosterol synthesis.
However, the vaginal preparations of boric
acid are not available in Tanzania markets
yet.
The relative resistance of the organisms to
azoles may be due to several reasons such as
extensive use of these compounds. This is
due to the fact that many cheap brands of
azoles exist in the market, a fact that may
influence not only prescription tendency but
also availability over the counter. In
addition, it is known that non-albicans
Candida species such as C. glabrata, C.
krusei, C. parapsilosis and C. tropicalis are
more resistant to treatment with azoles. This
is in line with studies done by White et al.
(1993, 1998, Singh et al. (1997), Sobel et al.
(2003), Ray et al. (2007) and Davies et al.
(2012). It should also be noted also that
some species such as C. norvegensis, C.
famata , C. krusei, C . parapsilosis, C.
lusitaniae, C. tropicalis, C. guilliermondii
and Trichosporon had very few isolates
(ranging from 1-8 isolates), which
contributed to the limited amount of data
obtained.
CONCLUSION
The evolving pattern of the non-albicans
Candida isolates, some of which with high
MIC values against azole antifungal drugs,
underlines the need for continuous
surveillance of the responsible Candida
species and determination of their
susceptibility to antifungal agents.
Treatment of VC was more successful with
boric acid followed by nystatin than azoles
antifungal agents for most Candida species.
There is a need to update the national
treatment guidelines for the treatment of
Candida vaginitis.
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